Anthracycline therapy induces an early decline of cardiac contractility in low-risk patients with breast cancer.
Anthracyclines
Breast cancer
CMR
Cardiotoxicity
Myocardial damage
Journal
Cardio-oncology (London, England)
ISSN: 2057-3804
Titre abrégé: Cardiooncology
Pays: England
ID NLM: 101689938
Informations de publication
Date de publication:
16 Jul 2024
16 Jul 2024
Historique:
received:
20
03
2024
accepted:
01
07
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
16
7
2024
Statut:
epublish
Résumé
Cancer therapy-related cardiac dysfunction (CTRCD) is a dreaded complication of anthracycline therapy. CTRCD most frequently appears in patients with cardiovascular risk factors (CVR) or known cardiovascular disease. However, limited data exist on incidence and course of anthracycline-induced CTRCD in patients without preexisting risk factors. We therefore aimed to longitudinally investigate a cohort of young women on anthracycline treatment due to breast cancer without cardiovascular risk factors or known cardiovascular disease (NCT03940625). We enrolled 59 women with primary breast cancer and scheduled anthracycline-based therapy, but without CVR or preexisting cardiovascular disease. We conducted a longitudinal assessment before, immediately and 12 months after cancer therapy with general laboratory, electrocardiograms, echocardiography and cardiovascular magnetic resonance (CMR), including myocardial relaxometry with T1, T2 and extracellular volume mapping. Every single patient experienced a drop in CMR-measured left ventricular ejection fraction (LVEF) of 6 ± 3% immediately after cancer therapy. According to the novel definition 32 patients (54.2%) developed CTRCD after 12 months defined by reduction in LVEF, global longitudinal strain (GLS) and/or biomarkers elevation, two of them were symptomatic. Global myocardial T2 relaxation times as well as myocardial mass increased coincidently with a decline in wall-thickening. While T2 values and myocardial mass normalized after 12 months, LVEF and GLS remained impaired. In every single patient anthracyclines induce a decline of myocardial contractility, even among patients without pre-existing risk factors for CTRCD. Our data suggest to thoroughly evaluate whether this may lead to an increased risk of future cardiovascular events.
Identifiants
pubmed: 39014463
doi: 10.1186/s40959-024-00244-y
pii: 10.1186/s40959-024-00244-y
doi:
Banques de données
ClinicalTrials.gov
['NCT03940625']
Types de publication
Journal Article
Langues
eng
Pagination
43Informations de copyright
© 2024. The Author(s).
Références
DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69:438–51. https://doi.org/10.3322/caac.21583 .
doi: 10.3322/caac.21583
pubmed: 31577379
Hendrick RE, Monticciolo DL, Biggs KW, Malak SF. Age distributions of breast cancer diagnosis and mortality by race and ethnicity in US women. Cancer. 2021;127:4384–92. https://doi.org/10.1002/cncr.33846 .
doi: 10.1002/cncr.33846
pubmed: 34427920
Arzanova E, Mayrovitz HN. The Epidemiology of Breast Cancer. In: Mayrovitz HN, editor. Breast Cancer. Brisbane: Exon Publications; 2022. Chapter 1.
Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13:R64. https://doi.org/10.1186/bcr2901 .
doi: 10.1186/bcr2901
pubmed: 21689398
pmcid: 3218953
Sawyer DB. Anthracyclines and heart failure. N Engl J Med. 2013;368:1154–6. https://doi.org/10.1056/NEJMcibr1214975 .
doi: 10.1056/NEJMcibr1214975
pubmed: 23514294
Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–42. https://doi.org/10.1038/nm.2919 .
doi: 10.1038/nm.2919
pubmed: 23104132
Lyu YL, Lin CP, Azarova AM, et al. Role of topoisomerase IIbeta in the expression of developmentally regulated genes. Mol Cell Biol. 2006;26:7929–41. https://doi.org/10.1128/MCB.00617-06 .
doi: 10.1128/MCB.00617-06
pubmed: 16923961
pmcid: 1636731
Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22:1945–60. https://doi.org/10.1002/ejhf.1920 .
doi: 10.1002/ejhf.1920
pubmed: 32463967
Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244 .
doi: 10.1093/eurheartj/ehac244
pubmed: 36017568
Spieker M, Haberkorn S, Gastl M, et al. Abnormal T2 mapping cardiovascular magnetic resonance correlates with adverse clinical outcome in patients with suspected acute myocarditis. J Cardiovasc Magn Reson. 2017;19:38. https://doi.org/10.1186/s12968-017-0350-x .
doi: 10.1186/s12968-017-0350-x
pubmed: 28351402
pmcid: 5370450
Bonner F, Janzarik N, Jacoby C, et al. Myocardial T2 mapping reveals age- and sex-related differences in volunteers. J Cardiovasc Magn Reson. 2015;17:9. https://doi.org/10.1186/s12968-015-0118-0 .
doi: 10.1186/s12968-015-0118-0
pubmed: 25656484
pmcid: 4318191
Garg P, Gosling R, Swoboda P, et al. Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications. Eur Heart J. 2022;43:2511–22. https://doi.org/10.1093/eurheartj/ehac207 .
doi: 10.1093/eurheartj/ehac207
pubmed: 35512290
pmcid: 9259376
Lancellotti P, Cosyns B, editors. The EACVI Echo Handbook. online ed. Oxford: ESC Publications; 2016. https://doi.org/10.1093/med/9780198713623.001.0001 . Accessed 5 July 2024.
Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37:1671–80. https://doi.org/10.1093/eurheartj/ehw022 .
doi: 10.1093/eurheartj/ehw022
pubmed: 26903532
pmcid: 4887703
Mecinaj A, Gulati G, Ree AH, et al. Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy-Related Cardiac Dysfunction. Cardio Oncol. 2024;6:83–95. https://doi.org/10.1016/j.jaccao.2023.10.008 .
doi: 10.1016/j.jaccao.2023.10.008
Lopez-Sendon J, Alvarez-Ortega C, Zamora Aunon P, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41:1720–9. https://doi.org/10.1093/eurheartj/ehaa006 .
doi: 10.1093/eurheartj/ehaa006
pubmed: 32016393
Safaei AM, Kamangar TM, Asadian S, et al. Detection of the early cardiotoxic effects of doxorubicin-containing chemotherapy regimens in patients with breast cancer through novel cardiac magnetic resonance imaging: a short-term follow-up. J Clin Imaging Sci. 2021;11:33. https://doi.org/10.25259/JCIS_58_2021 .
doi: 10.25259/JCIS_58_2021
pubmed: 34221642
pmcid: 8247694
Toro-Salazar OH, Gillan E, O’Loughlin MT, et al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging. 2013;6:873–80. https://doi.org/10.1161/CIRCIMAGING.113.000798 .
doi: 10.1161/CIRCIMAGING.113.000798
pubmed: 24097420
Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801. https://doi.org/10.1093/eurheartj/ehw211 .
doi: 10.1093/eurheartj/ehw211
pubmed: 27567406
Santoro C, Arpino G, Esposito R, et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging. 2017;18:930–6. https://doi.org/10.1093/ehjci/jex033 .
doi: 10.1093/ehjci/jex033
pubmed: 28379383
Oikonomou EK, Kokkinidis DG, Kampaktsis PN, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: A systematic review and meta-analysis. JAMA Cardiol. 2019;4:1007–18. https://doi.org/10.1001/jamacardio.2019.2952 .
doi: 10.1001/jamacardio.2019.2952
pubmed: 31433450
pmcid: 6705141
Thavendiranathan P, Negishi T, Somerset E, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021;77:392–401. https://doi.org/10.1016/j.jacc.2020.11.020 .
doi: 10.1016/j.jacc.2020.11.020
pubmed: 33220426
Galan-Arriola C, Lobo M, Vilchez-Tschischke JP, et al. Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol. 2019;73:779–91. https://doi.org/10.1016/j.jacc.2018.11.046 .
doi: 10.1016/j.jacc.2018.11.046
pubmed: 30784671
Martin-Garcia A, Diaz-Pelaez E, Lopez-Corral L, et al. T2 mapping identifies early anthracycline-induced cardiotoxicity in elderly patients with cancer. JACC Cardiovasc Imaging. 2020;13:1630–2. https://doi.org/10.1016/j.jcmg.2020.01.017 .
doi: 10.1016/j.jcmg.2020.01.017
pubmed: 32199840
Romano S, Judd RM, Kim RJ, et al. Feature-tracking global longitudinal strain predicts mortality in patients with preserved ejection fraction: A multicenter study. JACC Cardiovasc Imaging. 2020;13:940–7. https://doi.org/10.1016/j.jcmg.2019.10.004 .
doi: 10.1016/j.jcmg.2019.10.004
pubmed: 31727563
Thavendiranathan P, Shalmon T, Fan CS, et al. Comprehensive cardiovascular magnetic resonance tissue characterization and cardiotoxicity in women with breast cancer. JAMA Cardiol. 2023. https://doi.org/10.1001/jamacardio.2023.0494 .
doi: 10.1001/jamacardio.2023.0494
pubmed: 37043251
pmcid: 10099158
Lewinter C, Nielsen TH, Edfors LR, et al. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. Eur Heart J. 2022;43:2562–9. https://doi.org/10.1093/eurheartj/ehab843 .
doi: 10.1093/eurheartj/ehab843
pubmed: 34951629